1,721,026 research outputs found
Antibiotic treatment of Crohn's disease:results of a multicentre double blind randomized placebo controlled trial with Rifamixin
No full text1. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117-25.
Antibiotic treatment of Crohn's disease: results of a multicentre, double blind,
randomized, placebo-controlled trial with rifaximin.
Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F,
Cottone M.
Operative Unit of Gastroenterology, St Camillo-Forlanini Hospital, Rome, Italy.
[email protected]
BACKGROUND: Clinicians often employ antibiotics in Crohn's disease. Rifaximin is
active against bacteria frequently found in the intestinal mucosa of Crohn's
disease patients.
AIM: To evaluate the difference in efficacy between once and twice/daily oral
administration of rifaximin and placebo in the treatment of active Crohn's
disease.
METHODS: We enrolled 83 patients with mild-to-moderate Crohn's disease and
randomized to three treatments for 12 weeks: Group A (rifaximin 800 mg o.d. +
placebo), Group B (rifaximin 800 mg b.d.) and Group C (placebo b.d.).
RESULTS: Clinical remission was achieved by 52% of Group B, 32% (A) and 33% (C).
Clinical response was seen in 67% (B), 48% (A) and 41% (C), without reaching a
statistically significant difference. Treatment failures were: 4% (B), 12% (A)
and 33% (C), (P = 0.010). Remission and response rates of rifaximin 800 mg b.d.
were significantly higher than those of placebo and rifaximin 800 mg o.d. in
patients with elevated C reactive protein values (P < 0.05).
CONCLUSIONS: Rifaximin 800 mg b.d. was superior to placebo in inducing clinical
remission of active Crohn's disease. Although this difference was not
statistically significant, the number of the failures in the placebo group was
significantly higher than those who received rifaximin 800 mg b.d.
PMID: 16611272 [PubMed - indexed for MEDLINE
Indications,strategy and results of surgical management of 141 cases of Crohn's disease.
No full textA new oral delivery system for 5-ASA: preliminary clinical findings for MMx
No full textBackground: Multi-matrix (MMx), a new delivery system for mesalazine. seems to release 5-aminosalicyclic acid (5-ASA) preferentially in the sigmoid colon. This Study had 2 objectives: (1) to evaluate the therapeutic response to MMx in patients with active left-sided disease and (2) to gain additional insights as to how the therapy would compare with topical 5-ASA. Methods: Patients received either 1.2 g of 5-ASA MMx three times per day plus placebo enema or 4, of 5-ASA enema Plus placebo tablets for 8 weeks. The primary endpoint was clinical remission (clinical activity index &LE; 4) at 8 weeks. Secondary endpoints were endoscopic and histologic remissions. Results: Seventy-nine patients were enrolled. Clinical remission rates at 4 and 8 weeks were 57.5% and 60.0% for patients treated with MMx and 68.4% and 50.0% for patients randomized to 5-ASA enemas, respectively (95% confidence interval for the difference at 8 weeks, - 12 to + 32). Endoscopic remission was achieved by 45.0% of patients on 5-ASA MMx and by 36.8% of those on enema, whereas 15.0% and 8% of patients, respectively, showed histologic remission. Compliance was 97.0% for oral and 87.5% for topical therapy. In the enema group, compliance was 88.0% for the patients in remission and 65.5% for those with active disease. Conclusions: Preliminary studies suggest that similar rates for induction of remission can be expected from 5-ASA enemas and MMx for patients with left-sided Ulcerative colitis
Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn’s Disease
No full textBACKGROUND & AIMS: Bacteria might be involved in
the development and persistence of inflammation in patients
with Crohn’s disease (CD), and antibiotics could be
used in therapy. We performed a clinical phase 2 trial to
determine whether a gastroresistant formulation of rifaximin
(extended intestinal release [EIR]) induced remission in
patients with moderately active CD. METHODS: We performed
a multicenter, randomized, double-blind trial of the
efficacy and safety of 400, 800, and 1200 mg rifaximin-EIR,
given twice daily to 402 patients with moderately active CD
for 12 weeks. Data from patients given rifaximin-EIR were
compared with those from individuals given placebo, and
collected during a 12-week follow-up period. The primary
end point was remission (Crohn’s Disease Activity Index
150) at the end of the treatment period. RESULTS: At the
end of the 12-week treatment period, 62% of patients who
received the 800-mg dosage of rifaximin-EIR (61 of 98) were
in remission, compared with 43% of patients who received
placebo (43 of 101) (P .005). A difference was maintained
throughout the 12-week follow-up period (45% [40 of 89] vs
29% [28 of 98]; P .02). Remission was achieved by 54% (56
of 104) and 47% (47 of 99) of the patients given the 400-mg
and 1200-mg dosages of rifaximin-EIR, respectively; these
rates did not differ from those of placebo. Patients given the
400-mg and 800-mg dosages of rifaximin-EIR had low rates
of withdrawal from the study because of adverse events; rates
were significantly higher among patients given the 1200-mg
dosage (16% [16 of 99]). CONCLUSIONS: Administration
of 800 mg rifaximin-EIR twice daily for 12 weeks induced
remission with few adverse events in patients with moderately
active C
Recidiva precoce del morbo di Crohn e lesioni microscopiche dei margini della resezione intestinale.
No full textGoing Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Trattamento chirurgico e risultati in 60 casi di morbo di Crohn(MC) a localizzazione colica.
No full text- …
